On Friday 28 November, the annual HTA Work Programme for 2026 was adopted by the Member State Coordination Group on Health Technology Assessment (HTACG). The Work Programme outlines the key activities and strategic priorities of the group for the upcoming year.
The HTACG estimates that it will initiate around 50 joint clinical assessments (JCAs) of medicines with new active substances for the treatment of cancer and advanced therapy medicines. For the first time, the HTACG will launch JCAs of selected high-risk medical devices, with approximately 5 assessments expected to be initiated next year.
Health technology developers will also be able to submit requests for joint scientific consultations (JSCs) during the following request periods, published on the Europa website:
- 07 January to 04 February 2026
- 01 to 29 April 2026
- 03 June to 01 July 2026 and
- 23 September to 21 October 2026.
The report on emerging health technologies informed the Work Programme and the public version will be published shortly on the Europa website. Currently, 10 JCAs are ongoing and 7 JSCs have been initiated.
Excerpt from the official page. The original is authoritative.